NCT07061925

To Evaluate the Efficacy and Safety of ALC-2203 in Patients With Acute Bronchitis

A Randomized, Double-blind, Placebo- and Active-controlled, Parallel-group, Multicenter, Dose-finding, Phase 2 Clinical Trial to Evaluate the Efficacy and Safety of ALC-2203 in Patients With Acute Bronchitis

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 169 (actual)
• Sponsor: Korea Arlico Pharm. Co., Ltd · Industry
• Sex: All
• Age: 19 Years
• Healthy volunteers: Not accepted

Summary

A Randomized, Double-blind, Placebo- and Active-controlled, Parallel-group, Multicenter, Dose-finding, Phase 2 Clinical Trial to Evaluate the Efficacy and Safety of ALC-2203 in Patients with Acute Bronchitis

Conditions

• Acute Bronchitis

Interventions

Type	Name	Description
DRUG	ALC-2203-1	This group receives ALC-2203-1 and a placebo matching ALC-2203-AC, administered three times daily for 7 days.
DRUG	ALC-2203-2	This group receives ALC-2203-2 and a placebo matching ALC-2203-AC, administered three times daily for 7 days.
DRUG	ALC-2203-AC	This group receives a placebo matching ALC-2203-1 or ALC-2203-2, and ALC-2203-AC, administered three times daily for 7 days.
DRUG	Placabo	This group receives a placebo matching ALC-2203-1 or ALC-2203-2, and a placebo matching ALC-2203-AC, administered three times daily for 7 days.

Timeline

• Start date: 2025-04-23
• Primary completion: 2025-11-21
• Completion: 2025-11-26
• First posted: 2025-07-14
• Last updated: 2025-12-24

Locations

1 site across 1 country: South Korea